Volume 32, Issue 1 e13157
REVIEW ARTICLE

Renal protection strategies after heart transplantation

Daniel Reichart

Corresponding Author

Daniel Reichart

Department of Cardiovascular Surgery, , University Heart Center Hamburg, Hamburg, Germany

Correspondence

Daniel Reichart, MD, Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.

Email: [email protected]

Search for more papers by this author
Hermann Reichenspurner

Hermann Reichenspurner

Department of Cardiovascular Surgery, , University Heart Center Hamburg, Hamburg, Germany

Search for more papers by this author
Markus Johannes Barten

Markus Johannes Barten

Department of Cardiovascular Surgery, , University Heart Center Hamburg, Hamburg, Germany

Search for more papers by this author
First published: 19 November 2017
Citations: 7

Abstract

Renal dysfunction caused by calcineurin inhibitor (CNI) nephrotoxicity occurs often and contributes significantly to late mortality after heart transplantation (HTx). Over the last decades, this has prompted many clinical studies in an effort to develop kidney-protecting immunosuppressive strategies including delayed CNI start, minimization, withdrawal, or even de novo CNI avoidance. In the past, these strategies often failed due to the lack of efficacy. Since 2009, novel CNI-reducing strategies have been under investigation. These strategies minimize renal damage using induction agents such as antithymocyte globulin and alternative immunosuppressive agents such as the mechanistic target of rapamycin inhibitors (sirolimus or everolimus) or mycophenolate. This review outlines the recent results of using these renal protection strategies including their drawbacks. We also discuss alternative approaches to optimize individual immunosuppressive therapies after HTx.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.